(-) Teva halts tests of cancer drug biosimilar (Haaretz) - Oct 4, 2012 - Teva Pharmaceutical has suspended testing of generic version of rituximab at the third stage of clinical trials
Trial suspension • Biosimilar • Hematological Malignancies • Immunology • Rheumatoid Arthritis
|
|
Teva Pharmaceutical Industries has suspended testing of its generic version of Rituxan, a $7-billion a year drug, at the third stage of clinical trials.
The company is considering how best to meet the requirements from the U.S. Food and Drug Administration and those necessary for European medical certification...
|